IP Library › Granted Patent US 9,764,025
Granted Patent B2
US 9,764,025 · App. 14/887,965 · Granted Sep 19, 2017

Adaptation of attenuated infectious bronchitis virus (IBV) to embryonic kidney cells and vaccine thereby produced

Inventor: Haroldo E. Toro (Auburn, AL)
Assignee: Auburn University
A61K39/215A61K39/12C07K14/165C12N7/00A61K2039/5254A61K2039/545A61K2039/552A61K2039/57C12N2770/20034C12N2770/20064C12N2770/20071
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,764,025
App. No.
14/887,965
Granted
Sep 19, 2017
Kind
B2
Abstract

Disclosed are methods for preparing a vaccine against infection by infectious bronchitis virus (IBV). The methods typically include passing a heterogeneous attenuated population of IBV in chicken embryonic kidney cells, and optionally may include further passaging the heterogeneous attenuated population of IBV in embryonated chicken eggs (ECE) in order to obtain passaged attenuated population of IBV. Also disclosed are passaged attenuated populations of IBV in which the populations display a desired degree of homogeneity. Also disclosed are vaccines comprising the passaged attenuated populations of IBV and methods of vaccination comprising administering the disclosed vaccines.

Claims (21)

1. A method comprising passing a heterogeneous attenuated population of infectious bronchitis virus (IBV) in chicken embryonic kidney cells (CEKC) to obtain a passaged population of IBV, wherein the heterogenous attenuated population has less than about 95% homogeneity in the S1 polypeptide at an amino acid position selected from the group consisting of Ser at amino acid position 213 of the S1 polypeptide, Arg at amino acid position 323 of the S1 polypeptide, Arg at amino acid position 386 of the S1 polypeptide, Gln at amino acid position 398 of the S1 polypeptide, and His at amino acid position 399 of the S1 polypeptide; and wherein the passaged population has greater than about 95% homogeneity in the S1 polypeptide at the amino acid position selected from the group consisting of Ser at amino acid position 213 of the S1 polypeptide, Arg at amino acid position 323 of the S1 polypeptide, Arg at amino acid position 386 of the S1 polypeptide, Gln at amino acid position 398 of the S1 polypeptide, and His at amino acid position 399 of the S1 polypeptide.

2. The method of claim 1 , wherein:

(i) the heterogenous attenuated population has less than about 95% homogeneity in the S1 polypeptide at amino acid positions including Ser at amino acid position 213 of the S1 polypeptide, Arg at amino acid position 323 of the S1 polypeptide, Arg at amino acid position 386 of the S1 polypeptide, Gln at amino acid position 398 of the S1 polypeptide, and His at amino acid position 399 of the S1 polypeptide; and

(ii) the passaged population has greater than about 95% homogeneity in the S1 polypeptide at amino acid positions including Ser at amino acid position 213 of the S1 polypeptide, Arg at amino acid position 323 of the S1 polypeptide, Arg at amino acid position 386 of the S1 polypeptide, Gln at amino acid position 398 of the S1 polypeptide, and His at amino acid position 399 of the S1 polypeptide.

3. The method of claim 1 , wherein the heterogenous attenuated population has less than about 95% homogeneity with respect to Ser at amino acid position 213 of the S1 polypeptide and the passaged population has greater than about 95% homogeneity of Ser at amino acid position 213 of the S1 polypeptide.

4. The method of claim 1 , wherein the heterogeneous attenuated population of IBV is passaged in chicken embryonic kidney cells for at least 7 passages.

5. The method of claim 1 , further comprising further passaging the passaged population of IBV in embryonated chicken eggs.

6. A vaccine comprising a passaged attenuated population of IBV strain ArkDPI and a suitable carrier or excipient, wherein the passaged attenuated population of IBV exhibits at least about 95% homogeneity at amino acid positions in the S1 polypeptide including Ser at amino acid position 213 of the S1 polypeptide, Arg at amino acid position 323 of the S1 polypeptide, Arg at amino acid position 386 of the S1 polypeptide, Gln at amino acid position 398 of the S1 polypeptide, and His at amino acid position 399 of the S1 polypeptide.

7. A method for vaccinating a subject against infection by IBV, the method comprising administering to the subject the vaccine of claim 6 .

8. A method comprising passing a heterogeneous attenuated population of infectious bronchitis virus (IBV) Ark serotype in chicken embryonic kidney cells (CEKC) to obtain a passaged population, wherein the heterogenous attenuated population has less than about 95% homogeneity in the S1 polypeptide at an amino acid position selected from the group consisting of Ser at amino acid position 213 of the S1 polypeptide, Arg at amino acid position 323 of the S1 polypeptide, Arg at amino acid position 386 of the S1 polypeptide, Gln at amino acid position 398 of the S1 polypeptide, and His at amino acid position 399 of the S1 polypeptide, and wherein the passaged population has greater than about 95% homogeneity in the S1 polypeptide at the amino acid position selected from the group consisting of Ser at amino acid position 213 of the S1 polypeptide, Arg at amino acid position 323 of the S1 polypeptide, Arg at amino acid position 386 of the S1 polypeptide, Gln at amino acid position 398 of the S1 polypeptide, and His at amino acid position 399 of the S1 polypeptide.

9. The method of claim 8 , wherein:

(i) the heterogenous attenuated population has less than about 95% homogeneity in the S1 polypeptide at amino acid positions including Ser at amino acid position 213 of the S1 polypeptide, Arg at amino acid position 323 of the S1 polypeptide, Arg at amino acid position 386 of the S1 polypeptide, Gln at amino acid position 398 of the S1 polypeptide, and His at amino acid position 399 of the S1 polypeptide; and

(ii) the passaged population has greater than about 95% homogeneity in the S1 polypeptide at amino acid positions including Ser at amino acid position 213 of the S1 polypeptide, Arg at amino acid position 323 of the S1 polypeptide, Arg at amino acid position 386 of the S1 polypeptide, Gln at amino acid position 398 of the S1 polypeptide, and His at amino acid position 399 of the S1 polypeptide.

10. The method of claim 8 , wherein the heterogeneous attenuated population of IBV is passaged in chicken embryonic kidney cells for at least 7 passages.

11. The method of claim 8 , further comprising passaging the passaged population of IBV in embryonated chicken eggs.

12. A method comprising passing a heterogeneous attenuated population of infectious bronchitis virus (IBV) ArkDPI strain in chicken embryonic kidney cells (CEKC) to obtain a passaged population, wherein the heterogenous attenuated population has less than about 95% homogeneity in the S1 polypeptide at an amino acid position selected from the group consisting of Ser at amino acid position 213 of the S1 polypeptide, Arg at amino acid position 323 of the S1 polypeptide, Arg at amino acid position 386 of the S1 polypeptide, Gln at amino acid position 398 of the S1 polypeptide, and His at amino acid position 399 of the S1 polypeptide, and wherein the passaged population has greater than about 95% homogeneity in the S1 polypeptide at the amino acid position selected from the group consisting of Ser at amino acid position 213 of the S1 polypeptide, Arg at amino acid position 323 of the S1 polypeptide, Arg at amino acid position 386 of the S1 polypeptide, Gln at amino acid position 398 of the S1 polypeptide, and His at amino acid position 399 of the S1 polypeptide.

13. The method of claim 12 , wherein:

(i) the heterogenous attenuated population has less than about 95% homogeneity in the S1 polypeptide at amino acid positions including Ser at amino acid position 213 of the S1 polypeptide, Arg at amino acid position 323 of the S1 polypeptide, Arg at amino acid position 386 of the S1 polypeptide, Gln at amino acid position 398 of the S1 polypeptide, and His at amino acid position 399 of the S1 polypeptide; and

(ii) the passaged population has greater than about 95% homogeneity in the S1 polypeptide at amino acid positions including Ser at amino acid position 213 of the S1 polypeptide, Arg at amino acid position 323 of the S1 polypeptide, Arg at amino acid position 386 of the S1 polypeptide, Gln at amino acid position 398 of the S1 polypeptide, and His at amino acid position 399 of the S1 polypeptide.

14. The method of claim 12 , wherein the heterogeneous attenuated population of IBV is passaged in chicken embryonic kidney cells for at least 7 passages.

15. The method of claim 12 , further comprising passaging the passaged population of IBV in embryonated chicken eggs.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 27, 2015
From: TORO, HAROLDO E.
To: AUBURN UNIVERSITY
Reel/Frame 037149/0462 →
Continuity (2)
Provisional Application 62066135 · Oct 20, 2014
Related Publication 20160106828A1 · Apr 21, 2016